Skip to content

Revolution Medicines

US · RVMD #499 by market cap Listed 2020
161.20 +1.77 +1.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Revolution Medicines(RVMD.US) Officer Sells US$4.56 Million in Common Stock
    Market Newswire · 2026/11/19
  • Rating change
    RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $260
    Market Newswire · 2026/10/28
  • Rating change
    UBS Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $265
    Market Newswire · 2026/10/23
  • Bernstein Maintains Revolution Medicines(RVMD.US) With Hold Rating, Raises Target Price to $179
    Market Newswire · 2026/11/20
  • Rating change
    J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $289
    Market Newswire · 2026/11/10
  • Stifel Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $230
    Market Newswire · 2026/11/20
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT) and Revolution Medicines (RVMD)
    TipRanks · 2026/10/22
  • Rating change
    A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $222 to $340
    Market Newswire · 2026/11/6
  • Rating change
    H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $350
    Market Newswire · 2026/11/6
  • Rating change
    BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $264
    Market Newswire · 2026/10/26
  • Rating change
    TD Cowen Maintains Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $250
    Market Newswire · 2026/10/21
  • Revolution Medicines(RVMD.US) Officer Sells US$6.72 Million in Common Stock
    Market Newswire · 2026/11/14
  • Rating change
    Truist Financial Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $241
    Market Newswire · 2026/10/19
  • Rating change
    A Quick Look at Today's Ratings for Revolution Medicines(RVMD.US), With a Forecast Between $222 to $321
    Market Newswire · 2026/11/5
  • H.C. Wainwright Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $350
    Market Newswire · 2026/11/17
  • Rating change
    Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $247
    Market Newswire · 2026/11/13
  • Rating change
    J.P. Morgan Maintains Revolution Medicines(RVMD.US) With Buy Rating
    Market Newswire · 2026/10/21
  • Rating change
    Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $255
    Market Newswire · 2026/10/23
  • Rating change
    BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $274
    Market Newswire · 2026/11/13
  • Rating change
    Morgan Stanley Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $272
    Market Newswire · 2026/11/6
  • Rating change
    BofA Securities Maintains Revolution Medicines(RVMD.US) With Buy Rating, Cuts Target Price to $264
    Market Newswire · 2026/10/9
  • Rating change
    Guggenheim Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $275
    Market Newswire · 2026/10/16
  • Rating change
    Needham Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $275
    Market Newswire · 2026/10/15
  • Rating change
    LifeSci Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Maintains Target Price $315
    Market Newswire · 2026/10/5
  • Rating change
    RBC Capital Maintains Revolution Medicines(RVMD.US) With Buy Rating, Raises Target Price to $260
    Market Newswire · 2026/10/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:24 · For reference only, not investment advice and not tailored to your situation.

Revolution Medicines discussion 0 comments

Add a comment